Drugs Made In America Acquisition Corp. Units (DMAAU) — Net Asset Quality Index
Drugs Made In America Acquisition Corp. Units (DMAAU) has a Net Asset Quality Index of 97.0% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of $239.92 Million minus total liabilities of $7.28 Million yields net assets of $232.64 Million. A higher index indicates a stronger, lower-leverage balance sheet. Also explore Drugs Made In America Acquisition Corp. assets under control for the complete picture of this company's asset base.
Quality Index
Net Assets
Total Assets
Total Liabilities
Drugs Made In America Acquisition Corp. Units Net Asset Quality Index Over Time (2024–2025)
This chart shows how Drugs Made In America Acquisition Corp. Units's Net Asset Quality Index has evolved across 2 annual periods from 2024 to 2025. As of March 2026, the index stands at 97.0%, representing net assets of $232.64 Million against total assets of $239.92 Million USD. See working capital position of Drugs Made In America Acquisition Corp. to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Drugs Made In America Acquisition Corp. Units (2024–2025)
The table below presents the year-by-year Net Asset Quality Index for Drugs Made In America Acquisition Corp. Units from 2024 to 2025, covering 2 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see market value of Drugs Made In America Acquisition Corp. .
| Year | Quality Index | Net Assets (USD) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 97.0% | $232.64 Million | $239.92 Million | $7.28 Million | ▲ +141.4 pp |
| 2024 | -44.5% | $-244.85 | $550.82 | $795.67 | — |